• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc. (Amendment)

    2/13/24 4:59:03 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNY alert in real time by email
    SC 13G/A 1 tv0235-alnylampharmaceutical.htm SCHEDULE 13G/A alnylampharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 8)*

    Name of issuer:  Alnylam Pharmaceuticals Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  02043Q107

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  02043Q107

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    95,902

    7.  SOLE DISPOSITIVE POWER

    11,654,786

    8.  SHARED DISPOSITIVE POWER

    289,109

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    11,943,895

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.52%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Alnylam Pharmaceuticals Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    675 West Kendall Street, Henri A. Termeer Square
    Cambridge, MA 02142

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    02043Q107

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ALNY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNY

    DatePrice TargetRatingAnalyst
    8/4/2025Underperform → Peer Perform
    Wolfe Research
    8/4/2025$490.00Perform → Outperform
    Oppenheimer
    7/30/2025$370.00Outperform
    Raymond James
    7/21/2025$385.00Buy
    Truist
    3/31/2025$353.00Buy
    Redburn Atlantic
    3/24/2025$280.00 → $328.00Neutral → Overweight
    Analyst
    11/12/2024Peer Perform → Underperform
    Wolfe Research
    10/16/2024Sector Outperform
    Scotiabank
    More analyst ratings

    $ALNY
    SEC Filings

    View All

    SEC Form 10-Q filed by Alnylam Pharmaceuticals Inc.

    10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    7/31/25 8:11:22 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    7/31/25 8:05:29 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    6/18/25 4:48:38 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Reitan Colleen F bought $10,363 worth of shares (36 units at $287.85), sold $8,383 worth of shares (36 units at $232.86) and was granted 775 shares (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    5/12/25 4:05:00 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alnylam Pharma upgraded by Wolfe Research

    Wolfe Research upgraded Alnylam Pharma from Underperform to Peer Perform

    8/4/25 8:14:44 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharma upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Alnylam Pharma from Perform to Outperform and set a new price target of $490.00

    8/4/25 8:14:34 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Alnylam Pharma with a new price target

    Raymond James resumed coverage of Alnylam Pharma with a rating of Outperform and set a new price target of $370.00

    7/30/25 7:32:36 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ausiello Dennis A sold $13,729,536 worth of shares (31,448 units at $436.58) and exercised 31,448 shares at a strike of $131.34 (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    8/15/25 4:05:33 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CSO & EVP, Head of Research Fitzgerald Kevin Joseph was granted 7,763 shares, increasing direct ownership by 57% to 21,264 units (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    7/2/25 4:26:48 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Greenstreet Yvonne exercised 50,937 shares at a strike of $118.56 and sold $15,535,784 worth of shares (50,937 units at $305.00) (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    6/3/25 4:10:42 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

    - Company to Webcast Investor Event on August 30, 2025, at 1:00 p.m. EDT (7:00 pm CEST)- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain, from August 29 - September 1, 2025. These presentations will highlight the potential of RNAi therapeutics to transform the treatment of cardiovascular disease and reinforce Alnylam's commitment to advancing innovative therapies for patients living with rare and more prevalent conditions underserved by

    8/11/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference, on Tuesday, August 12, 2025 at 8:00 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharmaceuticals Alnylam (NASDAQ:ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and pre

    8/5/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

    − Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – − Achieved Approximately 1,400 ATTR-CM Patients on AMVUTTRA® (vutrisiran) as of June 30, 2025 – − Obtained Approvals for AMVUTTRA for the Treatment of ATTR-CM in the European Union, Brazil, the United Kingdom and Japan – − Initiated TRITON-CM Phase 3 Trial of Nucresiran in Patients with Wild-Type or Hereditary ATTR-CM – − Raises 2025 Guidance for TTR Franchise Net Revenues to $2,175 Million to $2,275 Million; Total Net Product Revenues to $2,650 Million to $2,800 Million, Representing a $575 Mil

    7/31/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

    4/30/24 1:44:03 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling

    9/20/23 2:36:38 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling

    2/17/23 12:30:09 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Financials

    Live finance-specific insights

    View All

    Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

    − Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – − Achieved Approximately 1,400 ATTR-CM Patients on AMVUTTRA® (vutrisiran) as of June 30, 2025 – − Obtained Approvals for AMVUTTRA for the Treatment of ATTR-CM in the European Union, Brazil, the United Kingdom and Japan – − Initiated TRITON-CM Phase 3 Trial of Nucresiran in Patients with Wild-Type or Hereditary ATTR-CM – − Raises 2025 Guidance for TTR Franchise Net Revenues to $2,175 Million to $2,275 Million; Total Net Product Revenues to $2,650 Million to $2,800 Million, Representing a $575 Mil

    7/31/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July 31, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2025 results as well as expectations for the future via conference call on Thursday, July 31, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceuti

    7/17/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

    − Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise – − Received U.S. Food and Drug Administration (FDA) Approval of AMVUTTRA® (vutrisiran) to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) – − AMVUTTRA ATTR-CM Launch Underway with Strong Progress Across All Early Commercial Indicators – − Approval of Qfitlia™ Represents the First and Only Therapeutic to Treat Hemophilia A or B With or Without Inhibitors and the Sixth Alnylam-Discovered

    5/1/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    11/12/24 9:50:12 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    11/8/24 10:34:33 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    8/12/24 9:40:06 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Leadership Updates

    Live Leadership Updates

    View All

    Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has

    3/5/25 7:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

    As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th

    3/5/24 9:06:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Announces Appointment of Peter Kellogg to Board of Directors

    – Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. "Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to achieving our P5x25 strategy and fulfilling our ambition to become a top-tier biopharmaceutical company," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "His financial expertise and experi

    3/8/23 7:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care